A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2022.02.033
PubMed Identifier: 35367282
Publication URI: http://europepmc.org/abstract/MED/35367282
Type: Journal Article/Review
Volume: 77
Parent Publication: Journal of hepatology
Issue: 2
ISSN: 0168-8278